Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000902664-25-003696
Filing Date
2025-08-14
Accepted
2025-08-14 17:03:28
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 9430
  Complete submission text file 0000902664-25-003696.txt   11179
Mailing Address 155 BOVET RD., SUITE 303 SAN MATEO CA 94402
Business Address 155 BOVET RD., SUITE 303 SAN MATEO CA 94402 (650) 561-8600
Sagimet Biosciences Inc. (Subject) CIK: 0001400118 (see all company filings)

EIN.: 205991472 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-94156 | Film No.: 251220760
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 72 CUMMINGS POINT ROAD STAMFORD CT 06902
Business Address 72 CUMMINGS POINT ROAD STAMFORD CT 06902 203-890-2000
Point72 Asset Management, L.P. (Filed by) CIK: 0001603466 (see all company filings)

EIN.: 465064661 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A